Dr. Androulakis is a Biomedical Engineering, Chemical & Biochemical Engineering Professor at Rutgers University. He is also a graduate faculty member in the Pharmaceutical Sciences as the Ernest Mario School of Pharmacy at Ritegrs University. He received his BS in Chemical Engineering from NTUA and his MS and Ph.D. from Purdue University. He was a research associate at Princeton University before joining ExxonMobil’s Corporate Strategic Research Laboratories. In 2004 he moved back to academia. He is a fellow of the American Institute of Medical and Biological Engineering and a Fellow of the American Institute of Chemical Engineers. He currently chairs the Quantitative Systems Pharmacology Special Interest Group of the International Society of Pharmacometrics. He has published extensively in quantitative systems biology and quantitative systems pharmacology.

Dr. Limei Cheng is an accomplished scientist with 20 years of experience in developing novel algorithms, modeling and simulations for healthcare applications such as quantitative systems pharmacology (QSP). She is currently the QSP Lead of Clinical Pharmacology and Pharmacometrics at (CP&P) at Incyte Corporation in Delaware. In her position, Dr Cheng uses model-based QSP approaches to integrate clinical and non-clinical data in a quantitative and mechanistic way to generate actionable predictions. Prior to joining Incyte, she led QSP-CV group in the department of CP&P at Bristol Myers Squibb (BMS) for almost 8 years. Prior to working at BMS, she spent 3+ years working at Philips Research North America in the Department of Clinical Decision Support Solutions. She began her career as a research associate at the Biomedical Simulation Resource (BMSR) in the Department of Biomedical Engineering at the University of Southern California (USC). Dr. Cheng has numerous recent presentations and publications demonstrating the utility of Systems Pharmacology in Pharmaceutical R&D. Dr. Cheng earned a B.E. in Biomedical Electronic Engineering from Xi’an Jiao Tong University, an M.S. in Electrical Engineering from the University of California, Los Angeles (UCLA), and a Ph.D. in Biomedical Engineering from USC. Her key areas of interest include QSP modeling, pharmacometrics, virtual population simulation, machine learning and AI, and personalized precision medicine.

Federico Reali, PhD, is Group Leader of the Quantitative Systems Pharmacology (QSP) group at Fondazione The Microsoft Research – University of Trento Centre for Computational and Systems Biology (COSBI). His expertise is in systems biology and QSP modeling applied to drug development across multiple therapeutic areas, including neurodegenerative disorders and lysosomal storage diseases. He leads and coordinates multidisciplinary research teams and collaborates with pharmaceutical companies and non-profit organizations on translational QSP projects. He is also a Teaching Fellow at the University of Trento, where he teaches probability and statistics and supervises undergraduate and graduate students. Federico Reali serves as Vice President of the Scientific Committee of the Italian National Life Sciences Cluster ALISEI. His current interests focus on using quantitative models, digital twins, and data-driven approaches to support clinical decision-making, therapeutic stratification, and the translation of complex biological data into clinically meaningful insights.

Alexander is a Chemist with a PhD focusing on theoretical and computational methods for structural and optical property predictions. He then spent several years in academia (U. of Lyon) working on molecular dynamics simulation and free energy methods dedicated to protein structure and aggregation. Alex moved to systems pharmacology applying large-scale disease and quantitative systems pharmacology models integrated into clinical trial simulations, across a number of disease areas. Alex is now leading the QSP team within ESQlabs with the aim to promote widespread application of integrated PBPK and QSP modeling. He is also currently affiliated at the pharmacy Department of University of Namur, working towards better qualifying PBPK/QSP for regulatory decision making. 

Conner Sandefur, PhD, is a Senior Scientist in QSP Solutions at Simulations Plus, where he develops mechanistic, systems-based models to support client decision-making and model‑informed drug development. His work focuses on injury and repair dynamics and nonlinear disease processes, with an emphasis on transparent, mechanism‑first model design that strengthens credibility across QSP applications.